News|Articles|November 7, 2025

The psychiatrist's guide to starting a private practice

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Integrating a Different Kind of Treatment Option into Schizophrenia Care: A Treating Physician’s Partnership-based Approach

April 6th 2026

Psychiatric Boarding in Emergency Departments: A Treatable Crisis

ByScott Zeller, MD

March 1st 2026

Sports Psychiatry and ADHD: A Vital Link in Neurodevelopment and Performance

ByUlrick Vieux, DO, CPE, MS, DFAPA,Ronke L. Babalola, MD, MPH ,Arrington, PsyD,Andrew Benotakeia, MD,Adriana Phan, MD

February 27th 2026

Recognizing Gaps in Treatment for Attention-Deficit Hyperactivity Disorder (ADHD)

November 19th 2025

Addressing Challenges of Nonadherence Among Adults With Schizophrenia

March 14th 2025

Latest CME

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

The psychiatrist's guide to starting a private practice

Related Content

Integrating a Different Kind of Treatment Option into Schizophrenia Care: A Treating Physician’s Partnership-based Approach

Psychiatric Boarding in Emergency Departments: A Treatable Crisis

Sports Psychiatry and ADHD: A Vital Link in Neurodevelopment and Performance

Recognizing Gaps in Treatment for Attention-Deficit Hyperactivity Disorder (ADHD)

Addressing Challenges of Nonadherence Among Adults With Schizophrenia

Latest CME

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Making Sense of the New Alzheimer Treatment Landscape, With Aaron Ritter, MD

Preventing Alzheimer Disease After Brain Injury: Targeting TNF With XPro1595

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

Real-World and Long-Term Trial Data Show Xanomeline/Trospium Cuts Hospitalizations, Antipsychotic Burden in Schizophrenia

PET Imaging Confirms Lower Muscarinic M1 Receptor Availability in Schizophrenia